The Cancer Drug Development Forum (CDDF) will hold a live webinar titled “Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe” on Tuesday, June 25 2024, at 16:00 (CEST) / 10:00 (EST).
WEBINAR OUTLINE
Under the joint leadership of the European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC), the Cancer Medicines Forum (CMF) serves as a pioneering initiative. Its primary goal is to seamlessly integrate the academic sector’s contributions into the regulatory decision-making process. Acting as a unique conduit between regulatory authorities and academic clinical research, the Cancer Medicines Forum facilitates the exchange of insights and expertise.
The deliverables of the Cancer Medicines Forum are strategically tailored to support policy decisions aimed at enhancing treatment optimization across Europe. Emphasizing post-licensing inquiries grounded in clinically relevant endpoints, the Cancer Medicines Forum endeavours to shape policy that prioritizes patient welfare within the healthcare landscape.
During the hybrid workshop held on April 5 2024, the Cancer Medicines Forum presented its astute observations and preliminary solutions to address treatment optimization.
This webinar, organized by the Cancer Drug Development Forum, provides a platform for Denis Lacombe (EORTC) to share the recommendations stemming from the workshop’s discussions. Join us as we delve into these critical insights shaping the future of cancer medicine.
Agenda: (CEST time zone)
16:00 – 16:05 Introduction – Rosa Giuliani (CDDF, UK)
16:05 – 16:30 Lecture by Denis Lacombe (EORTC, BE)
16:30 – 17:00 Panel Discussion – moderated by Rosa Giuliani (CDDF, UK)
Denis Lacombe
Denis Lacombe graduated with his MD from the University of Marseilles (France) in 1988 and obtained a Master Post-Doctoral Fellowship at The Roswell Park Cancer Institute (Buffalo, NY USA) for research in pharmacology and pharmacokinetics from 1989 to 1991. From 1991 to 1993, he worked as a Clinical Research Advisor in charge of the development of a new drug in oncology in the pharmaceutical industry.
Dr Lacombe joined the EORTC in 1993 as a research fellow and quickly became a very active and productive Clinical Research Physician involved in the conduct of clinical research from protocol development through publication for many oncology indications from phase I to phase III. Dr Lacombe contributed to the strategic evolution of the EORTC pan-European clinical and translational research infrastructure as well as developing partnerships with multiple stakeholders.
Dr Lacombe rose to the position of Director of EORTC Headquarters in 2010, was appointed Director General in April 2015 and Chief Executive Officer in June 2021. In his current position, Denis Lacombe leads all activities promoting the EORTC as a major European organization in Cancer Clinical and Translational Research, including scientific activities, public relations and medium-term strategies as defined by the EORTC Board as well as internal and external communications.
Dr Lacombe is the author of well over 100 peer-reviewed publications and communications.